Atomfair Inosine HXR, INO C10H12N4O5 CAS 58-63-9

Description

Inosine (CAS No. 58-63-9) is a naturally occurring nucleoside derived from hypoxanthine and ribose, with the molecular formula C₁₀H₁₂N₄O₅. This high-purity compound is widely utilized in biochemical research, pharmaceutical development, and as a precursor in nucleotide synthesis. Inosine plays a critical role in RNA translation, energy metabolism (e.g., ATP regeneration), and cellular signaling pathways, making it indispensable for studies in molecular biology, immunology, and neurology. Our product is rigorously tested for purity (≥99% by HPLC) and is supplied as a white crystalline powder with guaranteed stability under recommended storage conditions (-20°C). Ideal for in vitro assays, cell culture applications, and diagnostic reagent formulation.

Properties

• CAS Number: 58-63-9
• Complexity: 405
• IUPAC Name: 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one
• InChI: InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1
• InChI Key: UGQMRVRMYYASKQ-KQYNXXCUSA-N
• Exact Mass: 268.08076950
• Molecular Formula: C10H12N4O5
• Molecular Weight: 268.23
• SMILES: C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
• Topological: 129
• Monoisotopic Mass: 268.08076950
• Physical Description: White crystalline solid;
• Solubility: >40.2 [ug/mL]
• Synonyms: inosine, 58-63-9, Hypoxanthosine, Oxiamin, Ribonosine, Atorel, Hypoxanthine riboside, Trophicardyl, Selfer, Pantholic-L, Panholic-L, Hypoxanthine D-riboside, Hypoxanthine ribonucleoside, 9-beta-D-Ribofuranosylhypoxanthine, Hypoxanthine nucleoside, Inosina, Inosinum, Inosie, iso-prinosine, Inosine [INN:JAN], INO 495, Inosinum [INN-Latin], hypoxanthine-ribose, Inosina [INN-Spanish], Inosin, Inotin, Hypoxanthine, 9-beta-D-ribofuranosyl-, AI3-52241, NSC 20262, beta-D-Ribofuranoside, hypoxanthine-9, EINECS 200-390-4, Inotin (TN), DTXSID2045993, CHEBI:17596, 5A614L51CT, INOSINE [INN], INOSINE [JAN], INOSINE [MI], INOSINE [MART.], 9-.beta.-D-Ribofuranosylhypoxanthine, NSC-20262, INOSINE [WHO-DD], INOSINE [WHO-IP], 9-beta-D-ribofuranosyl-9H-purin-6-ol, INOSINE [USP IMPURITY], DTXCID0025993, 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one, 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one, DIDANOSINE IMPURITY B [WHO-IP], Inosinum (INN-Latin), 9-(beta-D-ribofuranosyl)-9H-purin-6-ol, ADENOSINE IMPURITY G [EP IMPURITY], Inosina (INN-Spanish), DIDANOSINE IMPURITY B [EP IMPURITY], INOSINE (MART.), 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one, INOSINE (USP IMPURITY), 9-.BETA.-D-RIBOFURANOSYL-1,9-DIHYDRO-6H-PURIN-6-ONE, 9-.BETA.-D-RIBOFURANOSYL-1,9-DIHYDRO-6H-PURIN-6-ONE [WHO-IP], (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-hydroxy-9H-purin-9-yl)tetrahydrofuran-3,4-diol, 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one, ADENOSINE IMPURITY G (EP IMPURITY), DIDANOSINE IMPURITY B (EP IMPURITY), betaInosine, Oxiamine, PanholicL, ()Inosine, 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-1H-purin-6-one, 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-3H-purin-6-one, 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6,9-dihydro-1H-purin-6-one, 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6,9-dihydro-3H-purin-6-one, Hypoxanthine Driboside, INOSINE [INCI], DIDANOSINE IMPURITY B, 9betaDRibofuranosylhypoxanthine, Hypoxanthine 9betaDribofuranoside, Hypoxanthine, 9betaDribofuranosyl, D06BB05, G01AX02, S01XA10, betaDRibofuranoside, hypoxanthine9, 1,9Dihydro9betaDribofuranosyl6Hpurin6one, 9-beta-D-ribofuranosyl-1,9-dihydro-6H-purin-6-one, 200-390-4, inchi=1/c10h12n4o5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17h,1h2,(h,11,12,18)/t4-,6-,7-,10-/m1/s, (-)-Inosine, beta-Inosine, INO, D-Inosine, Hypoxanthine 9-beta-D-ribofuranoside, MFCD00066770, HXR, Hypoxanthine-9-beta-D-ribofuranoside, MLS000028518, 9.beta.-D-Ribofuranosylhypoxanthine, 1,9-Dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one, CID 5274258, SMR000058316, .beta.-Inosine, (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-hydroxypurin-9-yl)oxolane-3,4-diol, 9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one, CAS-58-63-9, SR-01000721862, Catacol, NSC20262, UNII-5A614L51CT, 3h-inosine, 2ada, 2fqw, .beta.-D-Ribofuranoside, hypoxanthine-9, NCGC00095787-01, Adenosine Imp. G (EP); Inosine; Didanosine Imp. B (Ph. Int.); 9-beta-D-Ribofuranosyl-1,9-dihydro-6H-purin-6-one; Adenosine Impurity G; Didanosine Impurity B, Hypoxanthine, 9-.beta.-D-ribofuranosyl-, Inosine (JAN/INN), 1a4m, Inosine (8CI,9CI), Opera_ID_1628, bmse000098, bmse000888, bmse000978, cid_6021, CHEMBL1556, SCHEMBL15804, KBioGR_002560, KBioSS_002569, GTPL4554, SCHEMBL1682742, SCHEMBL3365586, SCHEMBL6933022, 9-b-D-Ribofuranosylhypoxanthine, Hypoxanthine-9-D-ribofuranoside, Inosine, >=99% (HPLC), SCHEMBL18653532, 9beta-D-Ribofuranosylhypoxanthine, BDBM22104, KBio2_002560, KBio2_005128, KBio2_007696, KBio3_003038, 9-|A-D-Ribofuranosylhypoxanthine, 9-b-D-ribofuranosyl-Hypoxanthine, MSK6812, cMAP_000084, HMS2235I17, Hypoxanthine-9-delta-ribofuranoside, 9-[(2S,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one, 9-beta-D-Ribofuranosyl-1,9-dihydro-6H-purin-6-one (Inosine), 9-beta-D-ribofuranosyl-Hypoxanthine, HY-N0092, 9beta-delta-Ribofuranosylhypoxanthine, Tox21_111522, BDBM50366815, beta-D-Ribofuranoside hypoxanthine-9, hypoxanthine-9 beta-D-Ribofuranoside, s2442, 9-beta-delta-Ribofuranosylhypoxanthine, AKOS015969695, AKOS015995607, AKOS024462561, Atorel; HXR; Hypoxanthine D-riboside, Tox21_111522_1, 9-beta-delta-ribofuranosyl-Hypoxanthine, CCG-267127, CS-5845, DB04335, NI06297, beta-delta-Ribofuranoside hypoxanthine-9, Hypoxanthine 9-beta-delta-ribofuranoside, hypoxanthine-9 beta-delta-Ribofuranoside, Hypoxanthine-9-beta-delta-ribofuranoside, SMP1_000165, NCGC00095787-05, NCGC00095787-06, NCGC00096119-02, NCGC00096119-03, AS-11754, BP-51105, DB-029916, I0037, NS00010210, C00294, D00054, EN300-310328, 1,9-dihydro-9-b-D-ribofuranosyl-6H-Purin-6-one, Q422564, SR-01000721862-2, SR-01000721862-3, AC89F8E4-FD89-45EE-8B41-94DFC07AB42F, BRD-K79612754-001-19-1, BRD-K79612754-001-21-7, 1,9-Dihydro-9-beta-delta-ribofuranosyl-6H-purin-6-one, 6H-Purin-6-one, 1,9-dihydro-9-beta-D-ribofuranosyl-, Z2681890654, 9-(3,4-DIHYDROXY-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-2-YL)-1,9-DIHYDRO-PURIN-6-ONE, 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one

Inosine is used as a substrate for enzymatic studies involving purine nucleoside phosphorylase (PNP) and inosine monophosphate dehydrogenase (IMPDH). It serves as a key intermediate in nucleotide biosynthesis and has been investigated for its neuroprotective and immunomodulatory properties. Additionally, inosine is employed in diagnostic kits for measuring PNP activity and in cell culture media to support metabolic demands.

Safety and Hazards

GHS Hazard Statements

• Not Classified
• Reported as not meeting GHS hazard criteria by 21 of 23 companies (only 8.7% companies provided GHS information). For more detailed information, please visit ECHA C&L website.

Hazard Classes and Categories

• Not Classified

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.